Florian Krismer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florian Krismer has a total of 651 co-authors. Here are the top co-authors by number of shared publications:
- Gregor Karl Wenning
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
49 shared publications Werner Poewe
44 shared publications- Klaus Seppi
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
42 shared publications Klaus Seppi
34 shared publications- Werner Poewe
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
21 shared publications Gregor K. Wenning
Department of Neurology Innsbruck Medical University Innsbruck Austria
17 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 154
Interest in clinical trial participation in Parkinson's disease: Insights from a nationwide registry
- 9 November 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 154
Open AccessInterest in clinical trial participation in Parkinson's disease: Insights from a nationwide registry
- Open Access
- 6 November 2026
- Published by Wiley in Movement Disorders
Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort
Background: Multiple system atrophy (MSA) is a rare neurodegenerative disorder that severely impairs health‐related quality of life (HRQoL). Disease progression is assessed using the Unified Multiple System Atrophy Rating Scale Part IV (UMSARS IV), which defines five stages. However, stage‐specific HRQoL estimates, particularly health‐utility values, are unavailable. These estimates are essential for health‐economic evaluation of treatments and for supporting HRQoL as a clinical trial endpoint. Bayesian methods offer a practical approach for analyzing HRQoL in rare diseases. Objective: To estimate EQ‐5D‐based health‐utility values across UMSARS IV stages in MSA. Methods: EQ‐5D data from the European MSA Study Group cohort were analyzed. EQ‐5D‐3L responses were mapped to EQ‐5D‐5L health‐utility values using the German value set, where a value of 1 represents perfect health and lower or negative values indicate worse health. Bayesian modeling estimated stage‐specific health‐utility values, reporting posterior means and 95% credible intervals (CrI). Sensitivity analyses included alternative model specifications and imputations of missing UMSARS IV stages. Results: Stage‐specific EQ‐5D‐5L health‐utility values were 0.672 (95% CrI 0.628–0.719) for UMSARS IV Stage 1, 0.606 (95% CrI 0.523–0.679) for Stage 2, 0.517 (95% CrI 0.416–0.615) for Stage 3, 0.262 (95% CrI 0.158–0.364) for Stage 4, and 0.084 (95% CrI −0.045 to 0.217) for Stage 5. Bayesian models demonstrated good fit, capturing variability within stages and across countries. Sensitivity analyses confirmed robustness, with health‐utility values reflecting expected MSA progression. Conclusions: This study is the first to provide stage‐specific health‐utility values across all UMSARS IV stages, enabling health‐economic evaluations of emerging interventions and supporting HRQoL as a clinical trial endpoint. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 6 November 2026
- Published by Wiley in Movement Disorders
Open AccessStage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort
Background: Multiple system atrophy (MSA) is a rare neurodegenerative disorder that severely impairs health‐related quality of life (HRQoL). Disease progression is assessed using the Unified Multiple System Atrophy Rating Scale Part IV (UMSARS IV), which defines five stages. However, stage‐specific HRQoL estimates, particularly health‐utility values, are unavailable. These estimates are essential for health‐economic evaluation of treatments and for supporting HRQoL as a clinical trial endpoint. Bayesian methods offer a practical approach for analyzing HRQoL in rare diseases. Objective: To estimate EQ‐5D‐based health‐utility values across UMSARS IV stages in MSA. Methods: EQ‐5D data from the European MSA Study Group cohort were analyzed. EQ‐5D‐3L responses were mapped to EQ‐5D‐5L health‐utility values using the German value set, where a value of 1 represents perfect health and lower or negative values indicate worse health. Bayesian modeling estimated stage‐specific health‐utility values, reporting posterior means and 95% credible intervals (CrI). Sensitivity analyses included alternative model specifications and imputations of missing UMSARS IV stages. Results: Stage‐specific EQ‐5D‐5L health‐utility values were 0.672 (95% CrI 0.628–0.719) for UMSARS IV Stage 1, 0.606 (95% CrI 0.523–0.679) for Stage 2, 0.517 (95% CrI 0.416–0.615) for Stage 3, 0.262 (95% CrI 0.158–0.364) for Stage 4, and 0.084 (95% CrI −0.045 to 0.217) for Stage 5. Bayesian models demonstrated good fit, capturing variability within stages and across countries. Sensitivity analyses confirmed robustness, with health‐utility values reflecting expected MSA progression. Conclusions: This study is the first to provide stage‐specific health‐utility values across all UMSARS IV stages, enabling health‐economic evaluations of emerging interventions and supporting HRQoL as a clinical trial endpoint. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 13 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (10) , 2638-2649
Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure
Background: The Movement Disorder Society (MDS) research criteria for possible prodromal multiple system atrophy (PP‐MSA) have not been prospectively validated. Objective: To evaluate the diagnostic performance of the PP‐MSA criteria in a longitudinal cohort of patients with pure autonomic failure (PAF) and to assess whether additional clinical features improve their predictive value. Methods: Seventy‐six patients with PAF enrolled across eight centers in the Natural History Study of the Synucleinopathies were followed for ≥6 years or until phenoconversion. Participants were classified according to MDS PP‐MSA criteria and followed for development of MSA, Parkinson's disease, or dementia with Lewy bodies. Diagnostic performance was assessed longitudinally. Analyses were repeated using a stricter olfactory threshold (University of Pennsylvania Smell Identification Test [UPSIT]≤28) as an exclusion criterion. Results: Thirty‐eight participants met PP‐MSA criteria, of whom 12 phenoconverted to MSA within 6 years. Sensitivity was 100% at year 1 and 92% at year 6, whereas specificity ranged from 56% to 67%. Positive predictive value (PPV) ranged from 21% to 34%. Applying a stricter olfactory threshold improved specificity (90%–97%) and PPV (53%–83%), with a modest reduction in sensitivity (to 83%). Participants who phenoconverted to MSA were younger, had more severe urinary dysfunction, and greater orthostatic heart rate responses. Conclusions: The PP‐MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF. A stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials. © 2026 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
- 13 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (10) , 2638-2649
Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure
Background: The Movement Disorder Society (MDS) research criteria for possible prodromal multiple system atrophy (PP‐MSA) have not been prospectively validated. Objective: To evaluate the diagnostic performance of the PP‐MSA criteria in a longitudinal cohort of patients with pure autonomic failure (PAF) and to assess whether additional clinical features improve their predictive value. Methods: Seventy‐six patients with PAF enrolled across eight centers in the Natural History Study of the Synucleinopathies were followed for ≥6 years or until phenoconversion. Participants were classified according to MDS PP‐MSA criteria and followed for development of MSA, Parkinson's disease, or dementia with Lewy bodies. Diagnostic performance was assessed longitudinally. Analyses were repeated using a stricter olfactory threshold (University of Pennsylvania Smell Identification Test [UPSIT]≤28) as an exclusion criterion. Results: Thirty‐eight participants met PP‐MSA criteria, of whom 12 phenoconverted to MSA within 6 years. Sensitivity was 100% at year 1 and 92% at year 6, whereas specificity ranged from 56% to 67%. Positive predictive value (PPV) ranged from 21% to 34%. Applying a stricter olfactory threshold improved specificity (90%–97%) and PPV (53%–83%), with a modest reduction in sensitivity (to 83%). Participants who phenoconverted to MSA were younger, had more severe urinary dysfunction, and greater orthostatic heart rate responses. Conclusions: The PP‐MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF. A stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials. © 2026 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
- Open Access
- 26 April 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (10) , 2539-2545
Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice
Background: Reduced cardiac uptake on 123 Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions. Objectives: This study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice. Methods: Patient records (2021–2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation. Results: Six hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug‐tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%. Conclusions: The clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.
- 26 April 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (10) , 2539-2545
Open AccessCardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice
Background: Reduced cardiac uptake on 123 Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions. Objectives: This study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice. Methods: Patient records (2021–2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation. Results: Six hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug‐tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%. Conclusions: The clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.
- Open Access
- 4 March 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (2)
Genotype and Age at Onset Drive Vermis Atrophy in CACNA1A- and GAA-FGF14-related Ataxias
CACNA1A - and GAA- FGF14 -related channelopathies are among the most frequent genetic etiologies of cerebellar ataxia. They display overlapping features consisting of both chronic and episodic neurological symptoms and usually show only a mild cerebellar atrophy in imaging studies, with prevalent involvement of the vermis. To evaluate cerebellar volumetry as a biomarker for distinguishing between these disorders and for understanding their neuroanatomical correlates. We applied a deep learning method (CerebNet) for the lobular segmentation and volumetry assessment of the cerebellum on 3.0 Tesla MRI scans of patients with genetically confirmed CACNA1A - (n = 16) and GAA- FGF14 -related (n = 12) ataxia. K-means clustering and principal component analysis were employed to assess infratentorial atrophy patterns. Three distinct clusters based on the patterns of infratentorial volume loss were established, with vermian atrophy contributing the most. The degree of vermian atrophy was not correlated with the clinical severity of chronic ataxia, but with age at disease onset ( r s (26) = 0.47, p = 0.01). The cluster with most marked atrophy of the vermis comprised patients with missense CACNA1A variants who exhibited an early disease onset and migraine with aura as episodic manifestation. Conversely, there was an increase in the frequency of episodic ataxia and both loss-of-function CACNA1A variants and GAA- FGF14 -expansions as genotypes when progressing from clusters with more to less severe vermian atrophy. Age at onset and the modality of channel dysfunction are key determinants of cerebellar volume loss in CACNA1A and GAA-FGF14 -disease.
- 4 March 2026
- Published by Springer Nature in The Cerebellum
- Vol. 25 (2)
Open AccessGenotype and Age at Onset Drive Vermis Atrophy in CACNA1A- and GAA-FGF14-related Ataxias
CACNA1A - and GAA- FGF14 -related channelopathies are among the most frequent genetic etiologies of cerebellar ataxia. They display overlapping features consisting of both chronic and episodic neurological symptoms and usually show only a mild cerebellar atrophy in imaging studies, with prevalent involvement of the vermis. To evaluate cerebellar volumetry as a biomarker for distinguishing between these disorders and for understanding their neuroanatomical correlates. We applied a deep learning method (CerebNet) for the lobular segmentation and volumetry assessment of the cerebellum on 3.0 Tesla MRI scans of patients with genetically confirmed CACNA1A - (n = 16) and GAA- FGF14 -related (n = 12) ataxia. K-means clustering and principal component analysis were employed to assess infratentorial atrophy patterns. Three distinct clusters based on the patterns of infratentorial volume loss were established, with vermian atrophy contributing the most. The degree of vermian atrophy was not correlated with the clinical severity of chronic ataxia, but with age at disease onset ( r s (26) = 0.47, p = 0.01). The cluster with most marked atrophy of the vermis comprised patients with missense CACNA1A variants who exhibited an early disease onset and migraine with aura as episodic manifestation. Conversely, there was an increase in the frequency of episodic ataxia and both loss-of-function CACNA1A variants and GAA- FGF14 -expansions as genotypes when progressing from clusters with more to less severe vermian atrophy. Age at onset and the modality of channel dysfunction are key determinants of cerebellar volume loss in CACNA1A and GAA-FGF14 -disease.
- Open Access
- 30 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70473
The Utility of Olfactory Testing to Discriminate Parkinson's Disease From Diagnostic Mimics: A Systematic Review and Meta‐Analysis
Background: Hyposmia is present in most patients with Parkinson's disease ( PD ), whereas olfaction is usually preserved in its diagnostic mimics. To address the limited evidence from smaller studies, we conducted a meta‐analysis on the diagnostic accuracy of olfactory testing in differentiating PD from clinical look‐alikes. Methods: A systematic search was performed in PubMed and Web of Science according to the PRISMA guidelines. Studies describing results of validated smell tests in PD patients and at least one differential diagnosis were included. The risk of bias and applicability was assessed with the QUADAS ‐2 tool. For data synthesis, a hierarchical regression model was employed. Results: Of 787 publications, 23 studies describing 1957 PD patients, 462 patients with atypical parkinsonian disorders, 239 patients with essential tremor, and 43 patients with secondary parkinsonism were included. The meta‐analysis demonstrated a sensitivity of 79% (95% confidence interval [ CI ]: 72%–84%) and a specificity of 81% (95% CI : 73%–86%) for olfactory dysfunction to differentiate PD from all other disorders combined. Additional analyses showed consistent sensitivities across sub‐analyses, with lowest specificities for the distinction from progressive supranuclear palsy, 64% (95% CI : 55%–72%), and highest from essential tremor, 92% (95% CI : 84%–96%). Conclusion: Our findings indicate that olfactory testing shows moderate to good diagnostic accuracy in differentiating PD from its main differential diagnoses. While results of olfactory testing alone are insufficient for a definite distinction of PD from non‐ PD parkinsonism, it represents an easy‐to‐use and inexpensive test that may be used in combination with other diagnostic tools.
- 30 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70473
Open AccessThe Utility of Olfactory Testing to Discriminate Parkinson's Disease From Diagnostic Mimics: A Systematic Review and Meta‐Analysis
Background: Hyposmia is present in most patients with Parkinson's disease ( PD ), whereas olfaction is usually preserved in its diagnostic mimics. To address the limited evidence from smaller studies, we conducted a meta‐analysis on the diagnostic accuracy of olfactory testing in differentiating PD from clinical look‐alikes. Methods: A systematic search was performed in PubMed and Web of Science according to the PRISMA guidelines. Studies describing results of validated smell tests in PD patients and at least one differential diagnosis were included. The risk of bias and applicability was assessed with the QUADAS ‐2 tool. For data synthesis, a hierarchical regression model was employed. Results: Of 787 publications, 23 studies describing 1957 PD patients, 462 patients with atypical parkinsonian disorders, 239 patients with essential tremor, and 43 patients with secondary parkinsonism were included. The meta‐analysis demonstrated a sensitivity of 79% (95% confidence interval [ CI ]: 72%–84%) and a specificity of 81% (95% CI : 73%–86%) for olfactory dysfunction to differentiate PD from all other disorders combined. Additional analyses showed consistent sensitivities across sub‐analyses, with lowest specificities for the distinction from progressive supranuclear palsy, 64% (95% CI : 55%–72%), and highest from essential tremor, 92% (95% CI : 84%–96%). Conclusion: Our findings indicate that olfactory testing shows moderate to good diagnostic accuracy in differentiating PD from its main differential diagnoses. While results of olfactory testing alone are insufficient for a definite distinction of PD from non‐ PD parkinsonism, it represents an easy‐to‐use and inexpensive test that may be used in combination with other diagnostic tools.
- Open Access
Multiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental parkinsonism
Multiple system atrophy (MSA) is an atypical Parkinsonian disorder marked by oligodendroglial α-synucleinopathy and selective neurodegeneration. Although MRI can capture regional atrophy and microstructural alterations in MSA brain, the molecular substrates underlying these phenotypes remain poorly defined. Imaging transcriptomics provides a computational framework to relate spatial imaging patterns to brain-wide gene expression. While this approach has been applied to human MSA, interpretation is constrained by limited experimental control and lack of disease-matched molecular validation. Here, we apply imaging transcriptomics in a controlled preclinical setting by integrating high-resolution ex vivo multimodal MRI with transcriptomic mapping in the PLP-αSyn mouse model of MSA. Structural and diffusion MRI revealed distinct patterns of regional atrophy and microstructural abnormalities. Atlas-based analyses associated imaging phenotypes to gene programs related to oligodendrocyte biology, energy metabolism, and neuroinflammation, with modality-specific signatures. These associations were supported by independent RNA-sequencing and showed convergence with human MSA findings. Our work benchmarks MRI–transcriptomic relationships in MSA and provides a translational framework for interpreting imaging biomarkers in synucleinopathies.
Open AccessMultiparametric MRI and imaging transcriptomics reveal molecular and cellular correlates of neurodegeneration in experimental parkinsonism
Multiple system atrophy (MSA) is an atypical Parkinsonian disorder marked by oligodendroglial α-synucleinopathy and selective neurodegeneration. Although MRI can capture regional atrophy and microstructural alterations in MSA brain, the molecular substrates underlying these phenotypes remain poorly defined. Imaging transcriptomics provides a computational framework to relate spatial imaging patterns to brain-wide gene expression. While this approach has been applied to human MSA, interpretation is constrained by limited experimental control and lack of disease-matched molecular validation. Here, we apply imaging transcriptomics in a controlled preclinical setting by integrating high-resolution ex vivo multimodal MRI with transcriptomic mapping in the PLP-αSyn mouse model of MSA. Structural and diffusion MRI revealed distinct patterns of regional atrophy and microstructural abnormalities. Atlas-based analyses associated imaging phenotypes to gene programs related to oligodendrocyte biology, energy metabolism, and neuroinflammation, with modality-specific signatures. These associations were supported by independent RNA-sequencing and showed convergence with human MSA findings. Our work benchmarks MRI–transcriptomic relationships in MSA and provides a translational framework for interpreting imaging biomarkers in synucleinopathies.
- Open Access
- 31 October 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 179-196
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment
Background and Objectives Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Little is known about available health-economic parameters for multiple system atrophy, and it remains unclear if the current available data are sufficient to construct an early health technology assessment. This assessment considered (i) if data gaps can be minimised or cost-effectiveness modelling can be facilitated by conducting literature searches for disease analogues, (ii) if an early health technology assessment is feasible with the currently available data, and (iii) the potential for developing user-friendly model interfaces in rare diseases. Methods Literature searches were conducted for economic evaluations and health-economic parameters (including costs, utilities, natural history of disease) for multiple system atrophy. The searches for disease analogues focussed on economic evaluations and showed a widespread use of functional or disability scales to inform model structures; we therefore used the unified multiple system atrophy rating scale part IV (global disability scale) to inform the model structure. Natural history of disease data were used to inform utilities and transition probabilities. Analyses of a hypothetical intervention were conducted from the perspective of the United Kingdom National Health Service with a cost-effectiveness threshold of £30,000 per quality-adjusted life year. The cost-effectiveness analysis was presented using a user-friendly interface in R Shiny, which provides stakeholders with an opportunity to explore results. Results Cost-effectiveness analyses were not identified for multiple system atrophy; however, two cost-of-illness, 20 quality-of-life, and nine natural history of disease studies were identified. Health-economic parameters were estimated from registry data, such as utilities and transition probabilities. A cost-effectiveness analysis was constructed for a hypothetical intervention despite evidence shortcomings, for example, aggregated cost data. An R Shiny app with a user-friendly interface was developed for stakeholders to change inputs and evaluate results. Discussion Literature searches for disease analogues proved useful for early modelling in multiple system atrophy, for example, to inform model structures, but surrogate data could only be used when sufficient granularity was available (e.g., micro costing). These findings suggest that early conceptual modelling can help identify data gaps and guide future evidence generation, such as selecting appropriate endpoints for natural history of disease studies. Cost-effectiveness results can be highly uncertain for rare diseases at these early stages and should be considered as part of an iterative modelling framework.
- 31 October 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 179-196
Open AccessCost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment
Background and Objectives Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Little is known about available health-economic parameters for multiple system atrophy, and it remains unclear if the current available data are sufficient to construct an early health technology assessment. This assessment considered (i) if data gaps can be minimised or cost-effectiveness modelling can be facilitated by conducting literature searches for disease analogues, (ii) if an early health technology assessment is feasible with the currently available data, and (iii) the potential for developing user-friendly model interfaces in rare diseases. Methods Literature searches were conducted for economic evaluations and health-economic parameters (including costs, utilities, natural history of disease) for multiple system atrophy. The searches for disease analogues focussed on economic evaluations and showed a widespread use of functional or disability scales to inform model structures; we therefore used the unified multiple system atrophy rating scale part IV (global disability scale) to inform the model structure. Natural history of disease data were used to inform utilities and transition probabilities. Analyses of a hypothetical intervention were conducted from the perspective of the United Kingdom National Health Service with a cost-effectiveness threshold of £30,000 per quality-adjusted life year. The cost-effectiveness analysis was presented using a user-friendly interface in R Shiny, which provides stakeholders with an opportunity to explore results. Results Cost-effectiveness analyses were not identified for multiple system atrophy; however, two cost-of-illness, 20 quality-of-life, and nine natural history of disease studies were identified. Health-economic parameters were estimated from registry data, such as utilities and transition probabilities. A cost-effectiveness analysis was constructed for a hypothetical intervention despite evidence shortcomings, for example, aggregated cost data. An R Shiny app with a user-friendly interface was developed for stakeholders to change inputs and evaluate results. Discussion Literature searches for disease analogues proved useful for early modelling in multiple system atrophy, for example, to inform model structures, but surrogate data could only be used when sufficient granularity was available (e.g., micro costing). These findings suggest that early conceptual modelling can help identify data gaps and guide future evidence generation, such as selecting appropriate endpoints for natural history of disease studies. Cost-effectiveness results can be highly uncertain for rare diseases at these early stages and should be considered as part of an iterative modelling framework.
- Open Access
- 22 September 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (12) , 2845-2847
Temporal Muscle Thickness Correlates with Functional Decline in Huntington's Disease
- 22 September 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (12) , 2845-2847
Open AccessTemporal Muscle Thickness Correlates with Functional Decline in Huntington's Disease
- Open Access
- 12 July 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (5) , 875-889
The role of neuro-imaging in multiple system atrophy
Neuroimaging plays a crucial role in diagnosing multiple system atrophy and monitoring progressive neurodegeneration in this fatal disease. Advanced MRI techniques and post-processing methods have demonstrated significant volume loss and microstructural changes in brain regions well known to be affected by MSA pathology. These observations can be exploited to support the differential diagnosis of MSA distinguishing it from Parkinson's disease and progressive supranuclear palsy with high sensitivity and specificity. Longitudinal studies reveal aggressive neurodegeneration in MSA, with notable atrophy rates in the cerebellum, pons, and putamen. Radiotracer imaging using PET and SPECT has shown characteristic disease-related patterns, aiding in differential diagnosis and tracking disease progression. Future research should focus on early diagnosis, particularly in prodromal stages, and the development of reliable biomarkers for clinical trials. Combining different neuroimaging modalities and machine learning algorithms can enhance diagnostic precision and provide a comprehensive understanding of MSA pathology.
- 12 July 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (5) , 875-889
Open AccessThe role of neuro-imaging in multiple system atrophy
Neuroimaging plays a crucial role in diagnosing multiple system atrophy and monitoring progressive neurodegeneration in this fatal disease. Advanced MRI techniques and post-processing methods have demonstrated significant volume loss and microstructural changes in brain regions well known to be affected by MSA pathology. These observations can be exploited to support the differential diagnosis of MSA distinguishing it from Parkinson's disease and progressive supranuclear palsy with high sensitivity and specificity. Longitudinal studies reveal aggressive neurodegeneration in MSA, with notable atrophy rates in the cerebellum, pons, and putamen. Radiotracer imaging using PET and SPECT has shown characteristic disease-related patterns, aiding in differential diagnosis and tracking disease progression. Future research should focus on early diagnosis, particularly in prodromal stages, and the development of reliable biomarkers for clinical trials. Combining different neuroimaging modalities and machine learning algorithms can enhance diagnostic precision and provide a comprehensive understanding of MSA pathology.